TORONTO, CANADA -- (July 2, 2019) Exact Imaging (www.exactimaging.com), the world's leader in high resolution micro-ultrasound systems enabling real-time imaging and biopsy guidance for the prostate, announced that it is the proud recipient of Frost & Sullivan’s 2019 Global Prostate Cancer Diagnostic Imaging Technology Innovation Award.
“Exact Imaging’s 29 MHz micro-ultrasound system, ExactVu™, offers a novel approach for targeted real-time biopsies as compared to conventional transrectal ultrasound,” says Durga Chandrupatla, Senior Research Analyst, Transformational Health at Frost & Sullivan. “Moreover, Exact Imaging offers healthcare providers with technical and financial freedom through attributes such as being a bed-side procedure, minimal hands-on experience required, low capital investments, and independence from mpMRI for prostate biopsy, thereby enhancing the overall unique selling proposition of its flagship ExactVu™ micro-ultrasound system.”
"We are proud to have our ExactVu micro-ultrasound platform be recognized as a truly transformational technology in the prostate cancer marketplace by Frost & Sullivan," says Randy AuCoin, Exact Imaging's President and CEO. "This is further validation of the significant value that our ExactVu micro-ultrasound platform is bringing to urologists globally. The ExactVu system provides clinicians with the highest real-time resolution for an imaging system that they can utilize in their clinics for performing targeted prostate biopsies quickly, effectively and across the prostate cancer pathway - from first biopsy to repeat biopsies and through to active surveillance monitoring. The goal is to provide the most powerful and cost-effective imaging platform that enables urologists to ultimately improve both the standard of care and patient outcomes.”
Frost & Sullivan Innovation Awards recognize companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis, and extensive secondary research to identify best practices in the industry.
About Exact Imaging
Exact Imaging (www.exactimaging.com) is the world’s leader in high-resolution micro-ultrasound systems enabling real-time imaging and guided biopsies in the urological market for prostate cancer. Exact Imaging’s ExactVu™ micro-ultrasound platform operates at 29 MHz and enables a whole new level of resolution with the benefits of ease of use, affordability, and is an extension of the current urological workflow. Using the Exact Imaging platform, urologists are able to visualize areas of interest in the prostate and specifically target biopsies at those areas. For those cases where MRI might assist, the FusionVu™ micro-US/MRI fusion application operates on the ExactVu micro-ultrasound platform and facilitates fast, simple MRI fusion-based targeting with the guidance of the micro-ultrasound system’s 70-micron real-time resolution. The ExactVu micro-ultrasound system including the FusionVu application has received regulatory approval in the European Union (CE Mark), the United States (FDA 510(k)), and Canada (Health Canada medical device license).
